---
title: "ONE MEDIA GROUP released its annual performance report, with a loss attributable to shareholders of HKD 25.831 million, an increase of 22.94% year-on-year"
description: "According to the Zhitong Finance APP, ONE MEDIA GROUP released its full-year performance for the year ending March 31, 2025, with a revenue of HKD 32.314 million, a year-on-year decrease of 18.2%; a l"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242171560.md"
published_at: "2025-05-28T09:59:02.000Z"
---

# ONE MEDIA GROUP released its annual performance report, with a loss attributable to shareholders of HKD 25.831 million, an increase of 22.94% year-on-year

> According to the Zhitong Finance APP, ONE MEDIA GROUP released its full-year performance for the year ending March 31, 2025, with a revenue of HKD 32.314 million, a year-on-year decrease of 18.2%; a loss attributable to shareholders of HKD 25.831 million, a year-on-year increase of 22.94%; and a basic loss per share of HKD 0.064

According to the Zhitong Finance APP, ONE MEDIA GROUP (00426) announced its annual results for the year ending March 31, 2025, with a revenue of HKD 32.314 million, a year-on-year decrease of 18.2%; a loss attributable to shareholders of HKD 25.831 million, a year-on-year increase of 22.94%; and a basic loss per share of HKD 0.064

### Related Stocks

- [00426.HK - ONE MEDIA GROUP](https://longbridge.com/en/quote/00426.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/en/news/275851575.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.